ArticleDrug delivery and translational research2025
Cell membrane fusion composite lipid nanocarrier: preparation and evaluation of anti-tumor effects.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer Therapy.Topics in current chemistry (Cham) · 2026Review
- Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer Therapy.Topics in current chemistry (Cham) · 2026Review
- Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations.Drug delivery and translational research · 2026Review
- Application of biomimetic approaches in the treatment of neurological disorders.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
With the advancements in nanotechnology and biomaterials science, the development of nanodrug delivery systems (Nano-DDSs) has provided opportunities for the realization of precise targeted treatment of malignant tumors. Liposomes have become a type of DDS with early clinical application and mature development due to their excellent tissue-targeting capacity and outstanding biocompatibility. However, several obstacles remain, such as recognition and clearance by the immune system, a short half-life, and poor tumor targeting. To address these problems, we propose a new method to transform liposomes, using fusion to reassemble the extracted natural cell membranes and artificial phospholipids to form a composite nanolipid carrier (recombined lipid nanocarriers (RLNs)). We evaluated the different types of cell membrane composite lipid nanocarriers based on parameters such as particle size, stability, drug loading and release capabilities, in vitro and in vivo tumor-targeting efficacy, and safety. The results indicated that these novel tumor cell-derived membrane fusion lipid nanocarriers exhibited promising antitumor effects and safety profiles, offering insights for precision cancer treatment.
Indexed as
Identifiers
39638935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.